Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

722 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnostic criteria for Susac syndrome.
Kleffner I, Dörr J, Ringelstein M, Gross CC, Böckenfeld Y, Schwindt W, Sundermann B, Lohmann H, Wersching H, Promesberger J, von Königsmarck N, Alex A, Guthoff R, Frijns CJ, Kappelle LJ, Jarius S, Wildemann B, Aktas O, Paul F, Wiendl H, Duning T; European Susac Consortium (EuSaC). Kleffner I, et al. Among authors: wiendl h. J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1287-1295. doi: 10.1136/jnnp-2016-314295. Epub 2016 Oct 25. J Neurol Neurosurg Psychiatry. 2016. PMID: 28103199 Review.
Dendritic cell vaccination in autoimmune disease.
Gross CC, Wiendl H. Gross CC, et al. Among authors: wiendl h. Curr Opin Rheumatol. 2013 Mar;25(2):268-74. doi: 10.1097/BOR.0b013e32835cb9f2. Curr Opin Rheumatol. 2013. PMID: 23370378 Review.
Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2.
Meuth SG, Göbel K, Kanyshkova T, Ehling P, Ritter MA, Schwindt W, Bielaszewska M, Lebiedz P, Coulon P, Herrmann AM, Storck W, Kohmann D, Müthing J, Pavenstädt H, Kuhlmann T, Karch H, Peters G, Budde T, Wiendl H, Pape HC. Meuth SG, et al. Among authors: wiendl h. Ann Neurol. 2013 Mar;73(3):419-29. doi: 10.1002/ana.23814. Epub 2013 Feb 19. Ann Neurol. 2013. PMID: 23424019
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: wiendl h. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765
722 results